Novartis’ TOBI Podhaler: Can Patient Satisfaction Overcome FDA’s Clinical Concerns?
This article was originally published in The Pink Sheet Daily
FDA seems to find the data from the pivotal trials of the inhalation powder drug-device combination for the management of cystic fibrosis patients with Pseudomonas aeruginosa something less than persuasive.
You may also be interested in...
Novartis’ inhalation powder version of the antibiotic tobramycin appears to be much more convenient in treating Pseudomonas aeruginosa infections in cystic fibrosis patients than the currently marketed nebulized solution (Tobi), but the appropriateness of the FEV1 endpoint is likely to be a matter of dispute during advisory committee review.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.